Cheshire, UK--(Marketwire - November 29, 2007) -
Protherics PLC
Application for Listing
London, UK; Brentwood, TN, US: 29 November - Protherics PLC ("Protherics"
or the "Company"), the international biopharmaceutical company focused on
critical care and cancer, announces that today, application has been made
to the UK Listing Authority and the London Stock Exchange for 253,211
ordinary shares of 2p each in the Company (the "Shares") to be admitted
to trading on the Official List and to trading on London Stock Exchange's
main market. The Shares have been allotted pursuant to the conversion of
EUR300,000 in nominal value of convertible loan notes (the "Notes") issued to CoVaccine BV on 2 November 2007.
The Notes were received under the terms of an agreement entered into by
the Company with CoVaccine BV on 6 June 2006 in respect of the
acquisition of CoVaccine's novel adjuvant CoVaccine HT™. Further
details are contained in the Company's announcements dated 7 June 2006
and 2 November 2007.
The Shares will rank equally with the existing issued ordinary shares of
the Company and are expected to commence trading around 4 December 2007.
Following admission of the Shares, the Company's issued share capital
will be 339,950,033 Ordinary Shares.
| Ends |
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit
www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange